Clinical Trial

A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R08b in Parkinson's Disease Patients With GBA1 Mutations

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
A Phase I/II Clinical Study to Evaluate the Tolerability, Safety, and Efficacy of VGN-R08b Intra-cerebroventricular injection in Parkinson's Disease Patients with GBA1 Mutations
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-02-09; most recent amendment 2026-04-30.
Trial Details
NCT Number NCT07414290
Lead Sponsor Shanghai Vitalgen BioPharma Co., Ltd.
Conditions Parkinson Disease (PD)
Enrollment 17 participants
Start Date 2026-05-25
Primary Completion 2027-09-01 (estimated)
Study Completion 2031-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-01